Mural Oncology (NASDAQ:MURA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.